StemCells Inc. (STEM) Advances Clinical Trial In Age-Related Macular Degeneration To Final Cohort
5/22/2014 9:28:36 AM
NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Each of the eight patients in this second cohort will receive a dose of 1 million stem cells into the most affected eye.
Help employers find you! Check out all the jobs and post your resume.
comments powered by